Ipsen: Morgan Stanley initiates at 'overweight'
(CercleFinance.com) - Morgan Stanley has initiated its coverage of the Ipsen share with an "overweight" recommendation and a target price of 130 euros, saying the "Glass half full" for the French pharma group.
"We argue risk-reward is now positively skewed, with potential delays to generic competition and optionality from the Clementia acquisition fuelling further BD value creation," it says in its comments.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.